Stockwinners Market Radar for November 25, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:07 EST Astellas announces approval of XTANDI by China's NMPA - Astellas Pharma announced that the China National Medical Products Administration approved a new drug application for XTANDI on November 18 for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. The approval by the NMPA was based on the results of an Asian multinational Phase 3, randomized, double-blind, placebo controlled efficacy and safety study of enzalutamide in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer who had disease progression despite ADT and a single-dose pharmacokinetic study in healthy Chinese volunteers.

18:34 EST PVH Corp. CEO: Apparel has been a segment under pressure - In an interview on CNBC's Mad Money, PVH Corp. CEO Manny Chirico said: We've tried to take a conservative approach to the holidays, but there is plenty of uncertainty out there... If current trends continue, we'll do better than expected... Our European business is off the charts... I think we've got the business back in a good place... Our exposure to China is 10%-15% as we go into 2020 versus 35%-40% five years ago... The impact of the tariffs really hasn't hit the economy yet... I think we can manage the tariffs in the short term.

18:25 EST Bristol-Myers CEO: We are working on seven new medicines to launch - In an interview on CNBC's Mad Money, Bristol-Myers (BMY) CEO Giovanni Caforio said: We have a great pipeline and great people... We are positioned to succeed... Our position in cell therapy is one of the great programs we have right now... We recently announced a partnership with Fitbit (FIT)... We think we can grow through technology... The next frontier for growth is the early stage of cancer... We take a responsible approach to drug pricing, but we see a need for change in the system...Renewing our portfolio was really the rationale for acquiring Celgene (CELG).

18:02 EST Ardelyx, Kyowa Kirin expand partnership with two new agreements - Ardelyx and Kyowa Kirin Co. announced the expansion of their partnership with two new agreements. In the first agreement, the companies have established a two-year research collaboration, whereby Ardelyx will execute a research plan, in which Kyowa Kirin will also join, to advance two of Ardelyx's ongoing research programs focused on the identification and design of compounds to two undisclosed targets. In return, Kyowa Kirin will pay Ardelyx $10M ($5M a year for two years) to support the ongoing research. Following the end of the research period, Kyowa Kirin will have the option to license any candidates nominated by the companies for further development and commercialization in certain specified territories, with additional commitments payable to Ardelyx of up to $10.5M in upfronts and up to $500M in development and sales milestones. The research collaboration will be governed by a joint research committee. Additional terms were not disclosed. Under the second agreement, Kyowa Kirin has made a $20M equity investment in Ardelyx at $6.96 for 2,873,563 shares.

17:41 EST Boeing awarded $172.23M Navy contract modification - Boeing awarded a $172.23M modification to a previously awarded cost-plus-fixed-fee, indefinite delivery/indefinite-quantity contract. This modification increases the ceiling of the contract to continue service life modifications to extend the operational service life from 6,000 flight hours to 10,000 flight hours of up to 23 F/A-18E/F aircraft. Work is expected to be completed in May 2022. No funds are being obligated at time of award; funds will be obligated on individual orders as they are issued. The Naval Air Systems Command is the contracting activity.

17:35 EST General Electric awarded $1.34B Army contract modification - General Electric was awarded a $1.34B modification to a contract for T700 engine deliveries in support of the Army H-60 and AH-64 programs, Navy H-60 programs, Air Force programs, Foreign Military Sales and other government agencies. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of December 31, 2024. U.S. Army Contracting Command is the contracting activity.

17:23 EST Zoetis EVP Fenton sells 12.7K shares of common stock - In a regulatory filing, Zoetis disclosed that its Executive Vice President Andrew Fenton sold 12.7K shares of common stock on November 21st. The total transaction size was $1.53M.

17:18 EST Safehold to replace Oritani Financial in S&P 600 at open on 12/3 - Valley National Bancorp (VLY) is acquiring Oritani Financial (ORIT) in a transaction expected to be completed soon pending final conditions.

17:03 EST Carlyle, T&D to acquire majority stake in Fortitude Re from AIG for about $1.8B - American International Group (AIG), Carlyle Group (CG), and T&D Holdings announced that a newly created Carlyle-managed fund, together with T&D, have partnered to acquire from AIG a 76.6 percent ownership interest in Fortitude Group Holdings, whose group companies operate as Fortitude Re, for approximately $1.8 billion. After closing, ownership interests in Fortitude Re will include Carlyle and its fund investors at 71.5 percent (including the 19.9 percent stake previously acquired by Carlyle in November 2018), T&D at 25 percent and AIG at 3.5 percent. AIG will receive a $500 million non-pro-rata distribution, which if not paid by the later of May 13, 2020 or transaction close will result in an additional payment from the new Carlyle-managed fund and T&D based on their Fortitude Re ownership interest. The transaction is expected to close in mid-2020, subject to required regulatory approvals and other customary closing conditions.

17:01 EST RGC Resources raises annual dividend 6.1% to 70c per share - The board of directors of RGC Resources declared a quarterly dividend of 17.5c per share on the company's common stock. The indicated annual dividend is 70c per share, a 4c or 6.1% per share increase over the prior annual level. The Company has now increased the annual dividend 16 consecutive years. John D'Orazio, President and CEO of RGC Resources, Inc., stated, "The 6.1% increase reflects our solid financial performance, confidence in our business strategy and our continued commitment to deliver dividend growth to our shareholders." The dividend will be paid on February 1, 2020 to shareholders of record on January 15, 2020. This is the Company's 303rd consecutive quarterly cash dividend.

16:49 EST Hanesbrands CFO Hytinen to leave company - HanesBrands announced that CFO Barry A. Hytinen has notified the company of his decision to leave Hanes to accept another career opportunity outside of the apparel industry. Hytinen will continue to serve as Hanes chief financial officer until the end of the fiscal year, Dec. 28, 2019. With the support of an outside search firm, Hanes will initiate a comprehensive search to fill the CFO role. The company will consider both internal and external candidates.

16:40 EST Nutanix up 18% to $33.92 after Q1 results beat estimates

16:36 EST ChemoCentryx trading resumes

16:31 EST Fulton Financial declares special cash dividend of 4c per share - The special dividend is payable on December 16 to shareholders of record as of December 4.

16:27 EST Dover's Cook Compression wins service contract from ISAB refinery - Cook Compression, part of Dover Precision Components and Dover, has been awarded a multi-year contract by ISAB S.r.l, a part of Lukoil Oil Company, to provide technical support, reconditioning and upgrades for reciprocating compressor valves and actuators. The contract encompasses support for 27 reciprocating compressors in the ISAB Sud and Nord refinery sites in Syracuse, Italy, on the island of Sicily. To support the rapid reconditioning requirements of the contract, and to offer similar services to other refineries in the region, Cook Compression has opened a satellite service facility in Sicily.

16:25 EST Global Ship Lease to acquire two containerships for $24.5M in aggregate - Global Ship Lease announced that it has agreed to acquire two 2004-built, 6,080 TEU Post-Panamax containerships for an aggregate purchase price of $24.5M and with charters in place to a leading liner operator for minimum 52 months / maximum 60 months. The vessels, which have bows optimized for fuel efficiency at lower operating speeds, are scheduled for delivery by the end of this year. The vessels are expected to generate aggregate Adjusted EBITDA of approximately $21M over the term of the contracted charters, assuming the median expiry dates. With these additions, the company's fleet will comprise 45 vessels with a total capacity of 249,622 TEU. The vessels are being acquired from Black Pearl Containers, a company controlled by the former shareholders of Poseidon Containers, with which the company merged in November 2018, and pursuant to the company's right of first refusal on all such containership purchase opportunities and divestments. The company has agreed debt finance in connection with the acquisition of these ships.

16:23 EST Profound Medical announces Health Canada approval of TULSA-PRO system - Profound Medical announced Health Canada approval of the TULSA-PRO system for the ablation of low to intermediate risk organ-confined prostate cancer. TULSA-PRO is a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging, or MRI, with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue. The TULSA-PRO system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men's functional abilities. Pursuant to a distribution, license and supply agreement entered into with Knight Therapeutics in April 2015, Knight acts as Profound's exclusive distributor for TULSA-PRO in Canada. The commercial opportunity for TULSA-PRO in Canada will be modest until such time that government reimbursement is established.

16:22 EST Capital Southwest declares 75c per share special dividend - Capital Southwest Corporation announced its board has declared a special dividend of 75c per share. This special dividend declared is in addition to the regular dividend of 40c per share and the supplemental dividend of 10c per share previously declared by the board on November 4. All dividends declared have the same ex-dividend and record date and will be paid to shareholders on December 31.

16:20 EST Hillenbrand names Andrew Kitzmiller as Chief Accounting Officer - Hillenbrand has named Andrew Kitzmiller as its Vice President, Chief Accounting Officer and Controller, effective November 21. As Hillenbrand's principal accounting officer, Kitzmiller will oversee enterprise-wide accounting operations, including internal and external financial reporting, and Sarbanes-Oxley compliance. Kitzmiller has nearly 20 years of finance experience and has been Vice President - Finance & Corporate Controller at Milacron Holdings Corp. since April 2019. Prior to joining Milacron in 2017, he held several finance roles at GE Aviation in Cincinnati, OH, including most recently as Controller in the Additive, Aviation Supply Chain and Engineering Divisions.

16:19 EST Palo Alto Networks reports deferred revenue grows 26% y/y to $3B

16:18 EST Golub Capital announces special distribution of 13c per share - Payable on December 30 to stockholders of record as of December 12.

16:17 EST Acuity Brands acquires LocusLabs - Acuity Brands announced it has acquired LocusLabs, an indoor mapping and location platform. The acquisition is not expected to materially impact the Acuity Brands' fiscal 2020 consolidated financial performance. Terms of the acquisition were not disclosed.

16:16 EST Navios Maritime Partners to acquire 11 vessels, liquidate Navios Europe I - Navios Maritime announced that it had a receivable of $48.2M from Navios Europe I. On November 22, an agreement was reached to liquidate Navios Europe I. The agreement is subject to definitive documentation which is expected to be completed by the end of 2019. It is expected that Navios Partners will acquire the five containerships owned by Navios Europe I with a net equity value approximately equal to the receivable. Navios Partners entered into a share purchase agreement for the acquisition of the following four drybulk vessels from an entity affiliated with its chairman and CEO for $37M in a transaction approved by the Conflicts Committee of the board of Navios Partners. The vessels are expected to be delivered in Navios Partners' owned fleet by December. The vessels are financed with a $37M loan from a financial institution with an amortization profile of ten years, annual interest of LIBOR plus 475 bps, and maturity in 2022. The loan facility has no capital repayment until September 2020 and may be prepaid at any time without penalty. Navios Partners agreed to bareboat charter-in two newbuilding Kamsarmax vessels, one subject to completion of documentation. Each vessel has approximately 81,000 dwt and is being bareboat chartered-in for ten years. Navios Partners has the option to acquire the vessels after the end of the fourth year for the remaining period of the bareboat charter. Assuming exercise of the option at the end of the ten-year period, the implied fixed interest rate is 4.5%.The vessels are expected to be delivered in each of the second and the third quarter of 2021.

16:15 EST Spirit Realty acquires 123 properties for $435M - Spirit Realty Capital, Inc. today that it acquired 123 single-tenant properties for approximately $435M in cash. The transaction was executed at an approximate 7.86% initial capitalization rate with rents of $34.2M, a weighted average remaining lease term of 8.7 years and approximately 2M leasable square feet. "We are excited to announce this transaction, which added many high-quality tenants and concepts to our portfolio, particularly in the restaurant, auto-related and home furnishings industries," stated Jackson Hsieh, President and Chief Executive Officer. "This transaction provided a unique opportunity to acquire high-quality real estate, in solid trade areas with tenants we know well at an attractive risk-adjusted return."

16:13 EST Capital Southwest closes sale of Media Recovery - Capital Southwest Corporation announced that it closed the sale of Media Recovery, d/b/a SpotSee, on November 25. Capital Southwest originally invested $5.4M in MRI in November 1997. The sale transaction resulted in total value to Capital Southwest, in the form of cash and a potential earnout, generally in line with the most recent quarterly valuation.

16:11 EST Caleres reports Q3 Famous Footwear SSS up 2.5 - The company says: Q3 saw "positive same-store-sales growth of 2.5% at Famous Footwear, the eighth consecutive year of positive back-to-school same-store-sales growth."

16:09 EST LSB Industries provides update on Pryor, El Dorado facilities - LSB Industries announced that the ammonia plant at its Pryor, Oklahoma chemical facility returned to service and resumed production on November 13, 2019 after the completion of its turnaround as startup took approximately 15 days longer relative to previously articulated expectations. As part of this extensive turnaround at Pryor, the company installed a new urea reactor which is currently being brought online and undergoing adjustments to optimize performance. Additionally, the ammonia plant at the company's El Dorado, Arkansas facility resumed production on November 19, 2019 after being taken out of service on November 3, 2019 in order to make adjustments that improved the production volume of its ammonia plant. Management estimates that the additional downtime at both Pryor and El Dorado will have an impact of approximately $8M-$9M on adjusted EBITDA for the fourth quarter of 2019 as compared to the outlook that management discussed as part of its third quarter earnings announcement.

16:09 EST HP Enterprise CEO says confident in ability to drive profitable growth - Antonio Neri says: "We had a very successful fiscal year, marked by strong and consistent performance. Through our disciplined execution, we improved profitability across the company and significantly exceeded our original non-GAAP earnings and cash flow outlook, while sharpening our focus, transforming our culture and delivering differentiated innovation to our customers as they accelerate their digital transformations. I am confident in our ability to drive sustainable, profitable growth as we continue to shift our portfolio to higher-value, software-defined solutions and execute our pivot to offering everything as a service by 2022," Neri continued. "Our strategy to deliver an edge-to-cloud platform-as-a-service is unmatched in the industry."

16:08 EST ChemoCentryx announces 'positive' topline data from Phase III avacopan trial - ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma announced positive topline data from the pivotal Phase III ADVOCATE trial of avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This global study, in which a total of 331 patients with acute ANCA vasculitis were enrolled, met both of its primary endpoints, disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham Vasculitis Activity Score, or BVAS. Remission was defined as a BVAS score of zero and being off glucocorticoid treatment for ANCA vasculitis for at least the preceding four weeks. The pre-specified primary endpoints were remission of acute vasculitis activity at week 26 and sustained remission at week 52, where avacopan therapy was at least statistically non-inferior to the currently used glucocorticoid-containing standard of care. The two primary endpoints were tested sequentially using a gatekeeping procedure to preserve the Type I error.

16:07 EST HP Enterprise reports Q4 gross margin 33.3%, up 260bps from last year

16:05 EST Acadia's Pimavanserin shows significant improvement in Schizophrenia treatment - ACADIA Pharmaceuticals announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment. No drug is approved by the FDA for the treatment of the negative symptoms of schizophrenia. Pimavanserin demonstrated a statistically significant improvement on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 total score, compared to placebo. A greater improvement in the NSA-16 total score compared to placebo was observed in the 53.8% of patients (n=107) who received the highest pimavanserin dose of 34 mg. In this study, pimavanserin did not separate from placebo on the key secondary endpoint, the Personal and Social Performance scale. ACADIA plans to commence a second pivotal study with the 34 mg dose of pimavanserin in the first half of 2020. Additional results from the ADVANCE study will be presented at future scientific meetings. In the study, pimavanserin was well-tolerated with high completion rates of approximately 86% in both the pimavanserin and placebo treatment groups and similar rates of adverse events between pimavanserin and placebo. Additionally, no clinically significant differences in vital signs, weight, metabolic syndrome or extrapyramidal symptoms were observed in the pimavanserin group compared to placebo.

16:04 EST Kindred Biosciences receives FDA approval of Zimeta - Kindred Biosciences announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine has approved Zimeta for the control of pyrexia in horses. Pyrexia, or fever, is associated with a number of underlying diseases and can result in significant negative outcomes, including dehydration, laminitis, muscle wasting, weight loss, and in some cases death. Among performance horses, fever can also lead to loss of training and competition days. There are more than eight million horses in the United States, and over one million are seen by a veterinarian for fever annually. Zimeta is the first and only FDA-approved medication for the control of pyrexia in horses.

16:03 EST Westpac CEO Brian Hartzer to step down - Westpac Group Chairman Lindsay Maxsted announced a number of executive and Board changes in the wake of the Austrac Statement of Claim. Chief Executive Officer, Brian Hartzer will be stepping down as CEO with current Chief Financial Officer, Peter King taking over as acting CEO, effective Monday, December 2. Current Chief Operating Officer, Gary Thursby will act as CFO. In addition to the executive changes, Maxsted also announced that Director Ewen Crouch has decided he will not seek re-election at the upcoming annual meeting. "The Board accepts the gravity of the issues raised by AUSTRAC," Maxsted said. "As was appropriate, we sought feedback from all our stakeholders including shareholders and having done so it became clear that Board and management changes were in the best interest of the Bank."

16:00 EST ChemoCentryx trading halted, news pending

15:16 EST FDA grants accelerated approval to Global Blood Therapeutics' Oxbryta - The U.S. Food and Drug Administration announced it has granted accelerated approval to Oxbryta for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older. Oxbryta was granted Accelerated Approval, which enables the FDA to approve drugs for serious conditions to fill an unmet medical need based on a result that is reasonably likely to predict a clinical benefit to patients. Further clinical trials are required to verify and describe Oxbryta's clinical benefit. The FDA granted the approval of Oxbryta to Global Blood Therapeutics.

15:15 EST Global Blood Therapeutics trading halted, news pending

14:57 EST Verra Mobililty CEO says M&A 'always' a part of strategy - Verra Mobility (VRRM) is a global player in smart transportation that focuses on smart cities, smart roadways, and the connected systems that tie them together. In an exclusive interview with The Fly, the company's chief executive officer David Roberts discussed Verra Mobility's approach to M&A following the acquisition of Pagatelia last year: "M&A has always been a part of our strategy. We've always been very thoughtful about the way we do it by looking at markets that are highly adjacent to our customers so we can either increase our ability to serve our customers or we can accelerate into new areas for future growth of the company. What Pagatelia represented was a deal inside of Europe. We had already bought a company in Europe about two years ago. This was kind of an enhancement of that to allow us to have relationships with toll authorities in southern Europe, which allows us to now offer the same or a similar program that we offer to commercial fleets here in the United States. Now we'll be able to start offering that in Europe, which is a big growth area for us. Outside of that, we always will look at M&A. We have a robust pipeline. We're always looking at opportunities to grow through M&A. And that's in the U.S. and abroad." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:43 EST Verra Mobility CEO says will 'definitely' continue to work with New York - Verra Mobility (VRRM) is a global player in smart transportation that focuses on smart cities, smart roadways, and the connected systems that tie them together. In an exclusive interview with The Fly, the company's chief executive officer David Roberts discussed the company's recent school zone speed safety camera systems contract with New York City and its government contract prospects elsewhere: "Definitely, we'll continue to work with New York. Part of what we do is we partner with state legislators around the legislation that enables photo enforcement. Within any state there has to be legislation that allows you to do photo enforcement, and that's something that we do as part of our business. We work with local legislators to create what you would call smart transportation or safety-related legislation that allow things like photo enforcement. And we do that not only in New York, but around the country. We plan on growing inside New York not only with the program in New York City, but also with the expansion of school bus. So you're now allowed to have cameras on the side of buses in New York state. Additionally, we are working within the state of Georgia to expand there with school zone speed. Currently, there are 21 states that have legislation that allows for photo enforcement, and we have customers in every one of those states." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:26 EST GigCapital Inc trading halted, news pending

14:04 EST Verra Mobililty CEO says M&A 'always' a part of strategy

14:04 EST Verra Mobility a 'leader' in toll management in North America, CEO says - Verra Mobility (VRRM) is a global player in smart transportation that focuses on smart cities, smart roadways, and the connected systems that tie them together. In an exclusive interview with The Fly, the company's chief executive officer David Roberts discussed Verra Mobility's mission and basic business model: "Verra Mobility is a global leader in smart transportation, which means that we provide technology-enabled services that our customers use to make transportation safer and easier. What that looks like is we serve two primary customers. The first one is commercial fleets. So we serve commercial fleets with toll management and violation solutions...we're the leader in that here in North America. We also do that in Europe, where we support commercial fleets for tolling and violation solutions. And we're also a leading provider of photo enforcement here in North America where we work with cities on their smart city initiatives and primarily looking at safety through photo enforcement. So that's red light cameras, speed cameras, school bus stop cameras, data and analytics related to that, things like that." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

13:38 EST Verra's Roberts sees some stability in shares after Platinum Equity move

13:38 EST Verra CEO say Q3 earnings growth related to NYC expansion

13:37 EST Verra Mobililty CEO says M&A 'always' a part of strategy

13:18 EST Applied DNA Sciences regains compliance with Nasdaq listing standards - Applied DNA Sciences announced that it has received notification from Nasdaq that the company has regained compliance with Nasdaq's minimum bid price and stockholders' equity rules and met the requirements of the Nasdaq Hearing Panel decision dated October 1, which requires that the company evidence compliance with all applicable criteria for continued listing on or before December 31. Accordingly, the company's common stock will continue to be listed on The Nasdaq Capital Market and Nasdaq considers the matter closed. Dr. James Hayward, president and CEO of Applied DNA, said, "With this matter now resolved, we remain focused on driving growth to create value for shareholders."

12:26 EST Full House jumps after Mario Gabelli mentions as gambling play - Shares of Full House Resorts are jumping after Mario Gabelli mentioned the company on CNBC as stock pick for gambling exposure. The shares are up 14% to $3.61 in midday trading.

12:13 EST Facebook introduces Facebook Viewpoints market research app - Erez Naveh, Product Manager at Facebook (FB), announced that "We're introducing Facebook Viewpoints, a new market research app that rewards people for participating in surveys, tasks and research. We believe the best way to make products better is to get insights directly from people who use them. We'll use these insights to improve products like Facebook, Instagram, WhatsApp, Portal and Oculus, and to benefit the broader community... We want to better understand how the use of social media like Facebook can impact people's well-being, so we're launching the Well-Being Survey. Information from this survey will help us build better products that aim to limit the negative impacts of social media and enhance the benefits." Shares of online survey development cloud-based software as a service company SurveyMonkey (SVMK) may react negatively on the news. Reference Link

12:07 EST Gabelli highlights NextEra Energy Partners as stock pick - Mario Gabelli is speaking on CNBC.

12:04 EST Teladoc up 3% to $83.76 after Mario Gabelli mention on CNBC

12:03 EST National Grid reaches agreement with New York to lift natural gas moratorium - National Grid said has reached an agreement with the State of New York to immediately lift its natural gas moratorium for all customers in Brooklyn, Queens and Long Island for approximately the next two years. National Grid will therefore proceed to connect those customer applications put on hold due to the moratorium and start processing all new applications. The agreement also provides a "framework for resolving the longer-term energy supply issues." Within three months, National Grid has committed to present options to meet New York's long-term gas supply needs. It said, "Following a consultation process through a series of public meetings, final long-term options will be identified, that reflect the public input, and should be agreed with the State by June 2020. This will allow for safe and adequate construction of long-term options. As part of this agreement, National Grid will offer $7 million in customer assistance to address hardships arising from the moratorium, invest $8 million in demand response and energy efficiency programs and make an additional $20 million investment in clean energy projects and clean tech business investments. With this agreement, National Grid is released from claims that the Company's franchise or license should be revoked in connection with the moratorium and the matter opened by the Public Service Commission is resolved."

12:00 EST Kirkland Lake Gold falls -16.0% - Kirkland Lake Gold is down -16.0%, or -$7.61 to $40.01.

12:00 EST Quad/Graphics rises 10.4% - Quad/Graphics is up 10.4%, or 41c to $4.29.

12:00 EST VelocityShares 3x Inv Natural Gas ETN rises 12.9% - VelocityShares 3x Inv Natural Gas ETN is up 12.9%, or $14.38 to $125.46.

11:18 EST Nutrien prepares to shut down Rocanville potash mine due to CN strike - Nutrien announced that it will be forced to curtail production at its largest potash mine, Rocanville, due to the CN rail strike. Employee notices were sent out indicating the mine will be shut down for 2 weeks starting on December 2. "It is extremely disappointing that in a year when the agricultural sector has been severely impacted by poor weather and trade disputes, the CN strike will add further hardship to the Canadian agriculture industry," said Chuck Magro, Nutrien's President and CEO. "Any further disruption will be harmful to our business, the Canadian economy, and Canada's competitive position and reputation as a reliable supplier of fertilizer and food. However, most concerning is the impact on our hundreds of employees for whom this creates great uncertainty and hardship leading up to the holiday seaso."

10:00 EST VelocityShares 3x Long Natural Gas ETN falls -11.8% - VelocityShares 3x Long Natural Gas ETN is down -11.8%, or -$1.78 to $13.27.

10:00 EST BlueLinx falls -32.5% - BlueLinx is down -32.5%, or -$4.04 to $8.40.

10:00 EST Myovant Sciences rises 7.3% - Myovant Sciences is up 7.3%, or $1.03 to $15.12.

09:56 EST DelMar Pharmaceuticals announces interim data on two Phase 2 trials of VAL-083 - DelMar Pharmaceuticals announced interim data on its two Phase 2 trials of VAL-083, the Company's lead compound for the treatment of glioblastoma multiforme. The data were presented in two posters at the 2019 Society for NeuroOncology Annual Meeting in Phoenix, Ariz. The first poster outlined the open-label, Phase 2 study of VAL-083 as a first-line treatment in newly-diagnosed, unmethylated GBM patients. This study has enrolled 23 out of a planned 30 patients as of the data cut-off date of November 2, 2019. For the 22 patients who had completed at least one cycle of treatment as of that date, median progression-free survival with VAL-083 is currently 9.9 months. For the 18 patients initially receiving the intended treatment dose median PFS is currently 10.4 months. While this is not a head-to-head trial, historically, temozolomide has been demonstrated to have 6.9 months PFS in unmethylated GBM patients. Other doses were also examined as part of the dose escalation aspect of the study, and all but the 20 mg/m2/day dose also demonstrated superior PFS to the historical comparator. A median of eight cycles of treatment has been received by all patients who had either completed treatment or remain in active treatment. Nine patients have received more than 10 cycles. This study is being conducted at Sun Yat-sen University Cancer Center in China. The second poster outlined interim data from two groups of patients receiving VAL-083 in the open-label, Phase 2 study in recurrent and adjuvant unmethylated GBM settings. The recurrent group is receiving second-line therapy with VAL-083 following TMZ failure. Sixty-two patients have been enrolled as of the data cut-off of November 15, 2019, with 35 patients having received an initial dose of 40 mg/m2/day and 27 having received an initial dose of 30 mg/m2/day. Median overall survival for the 60 patients who have completed at least one cycle of treatment is currently 7.5 months. For the 25 of those patients who initially received the intended treatment dose of 30 mg/m2/day, mOS is currently 10.6 months. While this is not a head-to-head trial, historically lomustine, which is the most commonly used chemotherapy for these patients, has demonstrated a mOS of 7.2 months. The second arm of this study, in which patients receive VAL-083 as adjuvant therapy following treatment with radiation and TMZ, was initiated in July 2019. As of the data cut-off of November 15, 2019, five patients have been enrolled and all patients remain alive on continued therapy. The study in recurrent and adjuvant GBM is being conducted at M.D. Anderson Cancer Center in Houston, Tex. Similar to prior experience with VAL-083, myelosuppression has been the most common adverse event observed. Four subjects have experienced a serious adverse event possibly related to VAL-083 in the newly-diagnosed group, eleven subjects have experienced a possibly drug-related SAE in the recurrent group, and no patients have experienced a possibly drug-related SAE in the adjuvant group as of the relevant data cut-off dates. The Company's current cash resources are expected to be sufficient to fund the Company's planned operations into the fourth quarter of calendar year 2020, and to allow for funding to top-line results for our newly-diagnosed and recurrent setting studies, and for full enrollment for the adjuvant study arm patients.

09:47 EST VelocityShares 3x Long Natural Gas ETN falls -10.8% - VelocityShares 3x Long Natural Gas ETN is down -10.8%, or -$1.63 to $13.42.

09:47 EST Canopy Growth rises 5.5% - Canopy Growth is up 5.5%, or $1.02 to $19.43.

09:47 EST VelocityShares 3x Inv Natural Gas ETN rises 11.2% - VelocityShares 3x Inv Natural Gas ETN is up 11.2%, or $12.47 to $123.55.

09:28 EST Rezolute appoints Nektar COO Gil Labrucherie to board of directors - Rezolute (RZLT) announced the appointment of Gil Labrucherie to its Board of Directors where he will serve as Chairman of the Audit Committee. Labrucherie is currently the COO and CFO of Nektar Therapeutics (NKTR).

09:16 EST Performance Shipping announces delivery of Aframax tanker Briolette - Performance Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/t Briolette, a 2011-built Aframax tanker vessel of 104,588 dwt that the Company entered into an agreement to purchase in June 2019.

09:11 EST Powerbridge says there is no negative effect from U.S.-China trade war - Powerbridge has provided clarity on its business effect from the ongoing U.S.-China trade war. At the macro level, the reduced trade between the U.S. and China has been made up by the increased trade by China with other countries. The overall China import/export levels have still been increasing. Of note, Powerbridge still services a very small percentage of the overall market, so would likely not experience effects from short-term macro moves in the market. Powerbridge's business is increasingly driven by the Chinese government push for trade and the upgrade or replacement of technology solutions with the latest technologies.

09:09 EST AudioCodes enters royalty buyout agreement with IIA - AudioCodes announced that it has entered into a royalty buyout agreement with the Israel National Authority for Technology and Innovation. AudioCodes Ltd. and its subsidiary, AudioCodes Development Ltd., participated in royalty-bearing research and development programs and had received grants from the IIA, under which AudioCodes paid royalties at the rate of 1.3%-5% on sales of products developed with funds provided by the IIA. AudioCodes' contingent net royalty liability to the IIA at the time of the Agreement was approximately $49M including interest to the date of the Agreement with different annual interest rates ranging up to 5%. As part of the Agreement, AudioCodes agreed to pay approximately $32.2M to the IIA (to settle the $49M debt in full) over 3 years starting 2019, in 3 annual installments. This expense will be included in the cost of revenues reported for the fourth quarter of 2019. Upon making this payment, AudioCodes will eliminate all future royalty obligations related to its anticipated revenues and save the associated future interest payments in future years related to the Debt. In 2018, annual royalty expenses to the IIA were approximately $3M. The elimination of future royalty payments following the Agreement, will have a positive impact on the reported gross margin starting in the first quarter of 2020.

09:05 EST Castor Maritime announces $11M senior secured debt financing - Castor Maritime announced the closing, through two of its ship-owning subsidiaries, of a $11M secured term loan facility with Alpha Bank. The loan is expected to be drawn down before the end of 2019. The Company intends to use the net proceeds from the Alpha Bank Financing to retire its $7.5M existing shareholder bridge loan and to fund its ongoing plans for growth. The Alpha Bank Financing will have a tenor of five years from the drawdown date and will bear interest at 3.50% plus LIBOR per annum.

09:04 EST viagogo acquires StubHub from eBay for $4.05B in cash - eBay and viagogo announced they have entered into a definitive agreement for eBay to sell StubHub to viagogo for a purchase price of $4.05B in cash. The sale is expected to close by the end of the first quarter of 2020, subject to regulatory approval and customary closing conditions. "We believe this transaction is a great outcome and maximizes long-term value for eBay shareholders," said Scott Schenkel, interim CEO of eBay. "Over the past several months, eBay's leadership team and Board of Directors have been engaged in a thorough review of our current strategies and portfolio, and we concluded that this was the best path forward for both eBay and StubHub. We firmly believe in the StubHub business and we are excited about its future growth potential with viagogo as its owner." Eric Baker, viagogo's founder and CEO, also co-founded StubHub while in business school, but left before the business was sold to eBay for $310M in 2007. "It has long been my wish to unite the two companies. I am so proud of how StubHub has grown over the years and excited about the possibilities for our shared future," Baker said. "Buyers will have a wider choice of tickets, and sellers will have a wider network of buyers. Bringing these two companies together creates a win-win for fans - more choice and better pricing."

09:02 EST STMicroelectronics, maxon collaborate on precision motor control - STMicroelectronics is working with maxon to accelerate the design of robotics applications and industrial servo drives. The companies will demonstrate a jointly developed servo control kit at sps 2019 trade show in Nuremberg, November 26-28. The EVALKIT-ROBOT-1 is a plug-and-play solution aimed to help users easily approach the world of precise positioning and high-end motion in servo drives and robotics. A maxon 100-Watt BLDC motor with built-on 1024-pulse incremental encoder is included in the kit, embodying the company's expertise in magnetic design in motors that ensures smoothness and balance to allow fine control even at low rotor speeds. The servo control board supplied with the kit contains ST's STSPIN32F0A intelligent 3-phase motor controller and a complete inverter stage built with ST power transistors ready to connect to the motor. Motor-control firmware is also included, making it easy for users to start the motor and begin sending commands.

09:00 EST viagogo acquires StubHub from eBay for $4.05B

09:00 EST La Jolla trading resumes

08:52 EST FuelCell expands board to five with appointment of Chris Groobey - FuelCell Energy announced that its Board of Directors has appointed Chris Groobey to serve as a new independent director, effective November 20th, 2019. Groobey was most recently a partner at the law firm Wilson, Sonsini, Goodrich & Rosati and previously was a partner with the law firm Baker & McKenzie. Groobey's appointment expands the Board to five directors, four of whom are independent. He will be a member of the Board's Executive, Nominating and Corporate Governance, Audit and Finance, and Compensation Committees.

08:50 EST Generex signs agreement to acquire 51% of ALTuCELL - Generex Biotechnology Corporation announced that the Company has signed a Stock Purchase Agreement to acquire a 51% controlling interest in ALTuCELL, a privately held biotechnology company, in a stock and cash transaction. With this agreement, Generex gains a broad patent portfolio for cell encapsulation technology and cellular therapy. The transaction is expected to close by the end of the year. The ALTuCELL patent portfolio includes global patents for the AltuCaps cell encapsulation platform, together with patents for the chemistry, manufacturing, and ultra-purification of capsules. ALTuCELL has also been granted a wide-ranging patent, Microencapsulation of Myofibroblasts Isolated from Wharton Jelly for Prevention and Treatment of Autoimmune and Inflammatory Diseases. Generex is pleased to offer this patent for partnering and licensing to generate new cell therapy products, and to enable stem cell companies to patent their cellular therapy products with global market protection. Generex announced ALTuCELL's recently filed patent, Alginate Microcapsules for Cell and Molecular Therapy that Secrete Bioactive Immune Molecules, which will pave the way for implanted cells that can secrete therapeutic antibodies to treat innumerable diseases including cancer, arthritis, psoriasis, and inflammatory bowel disease.

08:47 EST Predictive Oncology regains compliance with Nasdaq's minimum bid price rule - Predictive Oncology announced that based on a notification letter recently received from the Listing Qualifications Department of the Nasdaq Stock Market the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. On November 16, 2018, the Company received a notification letter from the Nasdaq indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement. According to the Notification Letter on Deficiency, if at any time during the Compliance Period, the closing bid price for the Company is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the 10 consecutive business days, beginning from October 29, 2019 to November 11, 2019, the closing bid price Of the Company's common stock has been at $1.00 per share or greater, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.

08:46 EST Neogen's Reveal 3-D for Peanut test approved by AOAC - Neogen has received approval from the AOAC Research Institute for its Reveal 3-D for Peanut test, which is designed to help prevent peanut residues from contaminating foods not intended to contain peanuts. The AOAC's Performance Tested Method Certification provides independent validation of the ability of the Reveal 3-D for Peanut test to accurately detect peanut residues in environmental samples. The test is used by food processors to ensure their production facilities are free of peanut residues before production begins - and help protect their food allergic consumers.

08:43 EST Ford issues safety recall for 72,718 Ranger vehicles in U.S. - Ford Motor Company is issuing a safety recall for select 2019 Ford Ranger vehicles. In affected vehicles, the inline electrical connector terminals for the tail lamps may be misaligned or not properly seated. Misaligned or improperly seated terminals can result in intermittent or inoperative tail lamps. Intermittent or inoperative tail lamps can result in loss of stop, turn, rear position, and reverse lamps, which can reduce the vehicle's visibility and may not fully alert other drivers that the vehicle is braking, turning, or reversing, increasing the risk of a crash. The high-mounted center stop lamp is not affected. Ford is not aware of any reports of accident or injury related to this condition. This action affects 72,718 vehicles in the U.S. and federal territories and 5,546 in Canada. Dealers will inspect the underbody inline connector and, if a terminal is loose, it will be re-pinned into a replacement connector, Ford stated.

08:40 EST Invictus MD Strategies closes termination of Authentic Brands Group agreement - INVICTUS MD STRATEGIES announced the completion, effective September 30, 2019, of the previously announced termination of its license agreement with ABG-HMX, LLC pursuant to an omnibus settlement and termination agreement. The Company sought and received regulatory approval from the TSX Venture Exchange to complete the termination. Further to the description of the terms and conditions of the Agreement in the Company's news release dated October 23, 2019, in accordance with TSXV requirements, the Agreement was amended to institute a minimum per share issue price of $0.12 as opposed to $0.11625 for any share consideration issued in connection with the Company's payment obligations under the Agreement.

08:36 EST Inphi announces coherent amplifier, linear driver shipments surpass 5M - Inphi Corporation announced that it has shipped more than 5 million 100/200G and emerging 400/600G coherent transimpedance amplifiers and linear driver ICs for long haul, metro, and data center interconnect applications.

08:34 EST Ideanomics announces agreement with Dasheng Licheng Financial Leasing - Ideanomics has announced an agreement with Dasheng Licheng Financial Leasing Co., Ltd. to provide an innovative lease financing program for AAA+-rated state-owned entities and other enterprise fleet operators. The agreement has been designed with a consortium of insurance companies as investing partners in order to make financing programs flexible enough to meet the needs of the burgeoning EV market. The insurance company partners include China Life, China Property Insurance, Pacific Insurance, Taiping Insurance, Ping An Insurance, and Urtrust Insurance. These partners have committed up to RMB 100B for the Inner Mongolia heavy duty trucks replacement project

08:33 EST Elon Musk says Tesla has received 200,000 orders for Cybertruck - Elon Musk said Sunday night that Tesla received 200,000 orders for its Cybertruck. Musk previously tweeted that Tesla had received 187,000 orders. Reference Link

08:30 EST CymaBay trading resumes

08:29 EST NetSol Technologies goes live with NFS Ascent in Hong Kong - NETSOL has successfully implemented its flagship NFS Ascent Retail Platform, consisting of its Omni Point of Sale and Contract Management System, for a leading German auto captive finance company with operations in Hong Kong. This implementation in Hong Kong is the latest in an ongoing series as part of a larger multi-country contract, originally signed in December 2015, to provide an existing NETSOL customer with an upgrade to the company's Next-Gen platform, NFS Ascent. The contract includes implementations, licenses, maintenance, services and expected customization fees for the platform covering deployments in 12 countries, altogether representing the largest contract in NETSOL company history. Hong Kong marks the eighth deployment to "Go Live" following successful implementations in Japan, China, South Africa, Thailand, New Zealand, Australia and South Korea.

08:28 EST AMERI Holdings awarded SuccessFactors application support contract - AMERI Holdings announced that it has been awarded a SuccessFactors application support contract by an existing high-tech customer that displaces a much larger incumbent vendor. The customer's operations span multiple industries, including retail and manufacturing, with over 85,000 employees worldwide and approximately 2,000 employees in its U.S. division. Ameri100 will support and enhance the integration of the customer's SuccessFactors Human Experience Management Business Suite implementation. SuccessFactors is integral to the customer's ability to attract and retain personnel tasked with developing solutions in the retail and manufacturing industries. Ameri100 will also utilize SAP's Cloud Platform Integration middleware to create and maintain interfaces with third-party vendors, such as automated payroll services and benefits providers.

08:23 EST Westpac Banking trading halted, news pending

08:19 EST Surface Oncology projects cash runway into 2022 - The company said, "Based upon its current operating plan, which includes the debt facility announced today and anticipated milestones under its Novartis (NVS) collaboration, Surface now has a projected cash runway into 2022."

08:18 EST Surface Oncology announces $25M debt financing from K2 HealthVentures - Surface Oncology announced it has secured a debt financing facility for up to $25M from K2 HealthVentures, a healthcare-focused specialty finance company. Surface received a first tranche of $7.5M upon closing. Two subsequent tranches totaling $17.5M will become available to the Company upon the achievement of certain milestones.

08:16 EST LiveXLive Media, Samsung announce production, distribution pact - LiveXLive Media (LIVX) announced that its content will be available via the Samsung (SSNLF) XR platform. The two companies will collaborate to bring music and technology projects to all Samsung devices and SamsungVR.com. Samsung XR, the industry's go-to app for the best in XR and 360 videos, delivers content daily and provides access to one of the largest high-quality libraries in the world. With LiveXLive in Samsung XR, viewers will be able to engage with tentpole music events through exciting next generation technology, including holographics, volumetric video and on-site augmented reality. In addition, viewers will have the opportunity to enjoy original long and short form VR and 360 content, including pilots and artist collaborations exclusive to LiveXLive. LiveXLive will capture ten exclusive events using Samsung technology. The content will be available through an embedded Samsung player on all LiveXLive platforms, SamsungVR.com and Samsung devices.

08:12 EST Revance submits BLA to FDA for DAXI to treat glabellar lines - Revance Therapeutics announced the company has submitted a Biologics License Application, or BLA, to the FDA for DaxibotulinumtoxinA for Injection, or DAXI, in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the SAKURA Phase 3 trials, which is the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar frown lines.

08:12 EST Adamis says FDA does not approve ZIMHI NDA in present form - Adamis Pharmaceuticals Corporation announced that after the close of U.S. markets on November 22nd, it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Adamis' ZIMHI high-dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. The questions raised by the FDA related generally to Chemistry, Manufacturing and Controls. The plan is to expand on the CMC testing that has already been provided to the FDA to satisfy the CRL items. No other clinical safety or efficacy issues were raised, and the New Drug Application will remain open until the CMC issues are resolved. Dr. Dennis Carlo, President and CEO of Adamis, stated, "Obviously, we are very surprised and disappointed. With a growing number of fatal overdoses as a result of more potent opioids like fentanyl, we believe there is an obvious need for higher dose forms of naloxone and we remain committed to bringing ZIMHI to the market. We believe the comments and recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA. We remain committed to this product and our mission to provide physicians and patients access to a higher dose of naloxone. We will take the Agency's suggestion and request a meeting as soon as reasonably possible to discuss our plan to resubmit the NDA."

08:09 EST Seattle Genetics announces Health Canada approval of ADCETRIS - Seattle Genetics announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS in combination with cyclophosphamide, doxorubicin, prednisone, or CHP, chemotherapy for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma, or sALCL, peripheral T-cell lymphoma-not otherwise specified, or PTCL-NOS, or angioimmunoblastic T-cell lymphoma, or AITL, whose tumours express CD30. The approval is based on positive results of the phase 3 ECHELON-2 clinical trial that compared ADCETRIS plus CHP to CHOP, or cyclophosphamide, doxorubicin, vincristine, prednisone. Health Canada granted a Priority Review Designation for this submission. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed on the surface of several types of PTCL.

08:08 EST MoneyGram says Ripple makes final $20M investment - MoneyGram announced that Ripple has made the final $20M investment in MoneyGram equity pursuant to Ripple's original $50M equity investment commitment made earlier this year. Ripple purchased the newly-issued equity from MoneyGram at $4.10 per share, which represents a significant premium to MoneyGram's current market price. This funding will support MoneyGram's operations as the company continues to increase volume and use of On-Demand Liquidity, Ripple's product that leverages the digital asset XRP to send money globally, instantly and reliably for fractions of a penny.

08:06 EST Avadel achieves enrollment target in REST-ON Phase 3 trial of FT218 - Avadel Pharmaceuticals announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for its once-nightly sodium oxybate, FT218. Additional patients currently in the screening process will also be allowed to enroll in the study if they meet eligibility criteria. The last patient's last visit is expected to occur by the end of the first quarter of 2020, with topline data expected in the second quarter of 2020. Based on the Company's industry research, it believes FT218, if approved by the FDA, has the potential to take a significant share of the twice-nightly sodium oxybate market. The REST-ON study is a double-blind, randomized, placebo-controlled Phase 3 trial to assess the efficacy and safety of once-nightly FT218, a formulation of sodium oxybate using Avadel's proprietary Micropump technology for extended-release oral suspension, in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. The REST-ON study is under a Special Protocol Assessment agreement with FDA.

08:05 EST Zogenix announces FDA acceptance of NDA filing, priority review for FINTEPLA - Zogenix announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for FINTEPLA for the treatment of seizures associated with Dravet syndrome. The FDA granted Priority Review for the NDA for FINTEPLA, which provides for a six-month review from the date of receipt, and assigned a Prescription Drug User Fee Act target action date of March 25, 2020. In its NDA filing acceptance letter, the FDA also stated that it is not currently planning to hold an advisory committee meeting to discuss the application for FINTEPLA. The NDA is based on data from two positive pivotal Phase 3 trials in Dravet syndrome and an interim analysis from an ongoing open-label extension study, which included 232 patients treated for up to 21 months. Zogenix is also investigating FINTEPLA in Lennox-Gastaut syndrome, another rare, severe childhood-onset epileptic syndrome, for which a Phase 3 trial is ongoing, with top-line data results anticipated in the first quarter of 2020.

08:03 EST Aquestive Therapeutics receives FDA approval for Exservan oral film - Aquestive Therapeutics announced that Exservan Oral Film received early-action approval from the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis, an orphan disease.

08:02 EST Mitcham Industries unit announces contract award for innovative MA-X Technology - Mitcham Industries announced that its Klein Marine Systems unit has recently received a contract from a leading autonomous underwater vehicle manufacturer to install its innovative MA-X technology on a next generation system for evaluation by the U.S. Navy.

08:00 EST CymaBay trading halted, news dissemination

07:46 EST OpenText commences tender offer for Carbonite at $23.00 per share -

07:30 EST Sorrento Therapeutics trading resumes

07:21 EST Yamana Gold announces exploration results for El Penon, Minera Florida mines - YAMANA announced exploration results for the El Penon and Minera Florida mines. Exploration Highlights, El Penon : Developed a new structural interpretation of faulting in the Angelina sector of the Deep Orito vein in 2019 that has been confirmed by drilling. Drilling intercepted wide, high-grade intervals of mineralization, indicating excellent potential for mineral reserve and mineral resource growth with the potential to further extend mine life. Discovered a second vein at the Laguna satellite deposit with significant intervals over good widths. Ongoing exploration and infill drilling of secondary veins in the core mine have produced good results from a number of structures, including Sorpresa, Dorada, and Aleste. Completed a machine-learning study in mid-2019 with GoldSpot Discoveries that generated numerous exploration targets that are advancing via systematic surface exploration. El Penon is a long life operation with decades of production. Historically, mine life has extended beyond mineral reserves at any given point in time. Year-over-year replacement of mined and depleted mineral resources has established a much longer mine life than suggested by mineral reserves alone. This is expected to continue. The new discoveries continue to demonstrate that the exploration potential at El Penon remains significant and mine life will exceed currently estimated mineral reserves. Exploration Highlights, Minera Florida: Drilling in the consolidated Minera Florida property generated strong results, including new veins at better than life-of-mine grades, indicating excellent potential to replace mining depletion by year-end. The PV Sur-Fantasma corridor continues to grow, with positive drill intercepts in a new discovery located between the two known mineralized zones. These intervals are considerably higher grade than life-of-mine grade. Intercepts in the Bandolera zone, located east of the Maqui fault, demonstrate potential for new discoveries in an underexplored sector of the property.

07:18 EST True Leaf secures three licenses from Health Canada for medical cannabis - True Leaf Cannabis Inc., a subsidiary of True Leaf Brands, announced it has secured licenses from Health Canada to cultivate, process and sell cannabis for medical purposes pursuant to the Cannabis Act for its 18,000 square foot True Leaf Campus facility in Lumby, British Columbia. The license allows True Leaf to begin cultivating, processing and selling medical cannabis from its facility immediately and to produce alternative cannabis products such as edibles, topicals, and capsules. True Leaf Campus sits on a 40-acre site of industrial zoned land wholly owned by True Leaf. During the licensing process, the Company entered the pet industry with True Leaf Pet, a natural pet care brand with a suite of hemp- and CBD-based pet products now sold in 3,500 stores across North America, Europe, and Asia.

07:15 EST Enochian Biosciences to acquire exclusive license for HBV treatment - Enochian Biosciences announces the expansion of its infectious disease pipeline by entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus infections from G-Tech Bio, LLC. An abstract accepted for presentation at the HepDART meeting featuring in vivo and in vitro data from preclinical studies conducted with this novel HBV treatment candidate will be presented by Dr. Serhat Gumrukcu, MD, PhD on December 10, 2019. Approximately 5 percent of the world's population is infected with HBV, and around 1 million people per year die from the disease. The company said, Based on the determinations from independent valuation specialists as contained in our audited financial statements for our fiscal year ended June 30, 2019, our intangible assets related primarily to our HIV pipeline are approximately $154.8M. The addition of a treatment that we believe could have the potential to cure HBV expands an already exciting pipeline for Enochian. Enochian licenses are for intellectual property that include proprietary know-how and pending patent applications covering aspects of our pipeline therapeutics. Additionally, Enochian intends to protect the therapeutics that may be approved for marketing in the future with regulatory exclusivity that is available in many jurisdictions around the world. These exclusivity strategies, which are based on pending patent applications, patents, if issued, and regulatory exclusivity, are common among biotech companies as therapeutic candidates proceed through pre-clinical and clinical stages leading to commercialization...Enochian has recently entered into agreements that upon satisfaction of certain closing conditions and closing will provide an additional $12 million in funding. Based on current projections, we believe these resources should be sufficient to advance the pipeline through pre-clinical phases into Phase I trials if IND approvals are secured"

07:11 EST Microbot Medical issued notice of allowance for patent covering TipCAT platform - Microbot Medical was issued a Notice of Allowance for patent application No. 15/936,878 by the U.S. Patent and Trademark Office. The allowed patent application covers the Company's TipCAT technology platform. The allowed patent application is a Continuation of Patent No. 9,937,326, issued on April 10, 2018, which is a Continuation of Patent No. 9,061,118, issued on June 23, 2015. It covers a self-propelled device for locomotion through a lumen, the device comprising a set of serially arranged inflatable chambers configured for sequential inflation from a single fluid source, wherein the outer skin of at least one of the chambers has at least one longitudinal section of greater rigidity than other sections of the outer skin, such that when that chamber inflates, the set of chambers transitions to a bent state.

07:09 EST Drinkworks announces market entry into Illinois ahead of holiday season - Drinkworks announced market entry into Illinois ahead of Black Friday and the busy holiday shopping season. The company additionally announced that cocktail enthusiasts in Arizona, Washington, Minnesota, Nevada, Maryland and the District of Columbia now have the opportunity to preorder the Drinkworks Home Bar by Keurig, with fulfillment beginning in 2020.MSRP for the Drinkworks Home Bar by Keurig is $399, and the brand is offering a series of promotions through the end of the year for consumers in all available markets.

07:07 EST Brainsway aims to begin opioid abuse study in 1Q20 - The company said, "Completed planned protocol for opioid abuse study; the Company expects to submit an investigational new device application with the FDA and, if approved, begin the trial in Q1 2020."

07:06 EST Carrols Restaurant names Anthony Hull as CFO - Carrols Restaurant (TAST) announced that it has appointed Anthony Hull as the company's VP, CFO and treasurer effective January 2, 2020. Hull most recently served a senior advisor on corporate strategy and capital markets projects at Realogy (RLGY). and previously was the company's executive VP, CFO and treasurer from 2006 to 2018. During his tenure, he was responsible for financial and strategic planning, accounting, budgeting, capital structure, controls and compliance, mergers and acquisitions, procurement and facilities.

07:06 EST Qudian completes cancellation of $195M of American depositary shares - Qudian announced that the company has completed the cancellation of $195M worth of its outstanding American depositary shares representing its Class A ordinary shares. A total of 26,169,241 ADSs were cancelled, effective November 25. The cancelled ADSs were previously purchased under Qudian's share repurchase program announced on August 23, and represent approximately 10% of the outstanding shares of the company.

07:04 EST Rexford Industrial acquires three industrial properties for $56.1M - Rexford Industrial announced the acquisition of three industrial properties for $56.1M. The acquisitions were funded using cash on hand. The company acquired 415 S. Motor Ave, located in Azusa within the LA - San Gabriel Valley submarket, comprising 4.2 acres, for $7.2 M or $39 per land square foot. The company acquired 508 East E Street, located in Wilmington within the LA - South Bay submarket, for $14.9M, or $259 per square foot. The company acquired 12752-12822 Monarch Street, located in Garden Grove within the Orange County - West submarket, for $34M, or $130 per square foot of building, equal to $70.00 per square foot of land.

07:02 EST CytoSorbents temporarily pauses enrollment in REFRESH 2-AKI study - CytoSorbents is temporarily pausing enrollment of its REFRESH 2-AKI study at the recommendation of its Data Monitoring Committee as the company transitions to a new contract research organization for the trial. The DMC recommended this pause following a blinded, interim, milestone review of clinical study data. The DMC requested that additional data analysis and clinical data, not pre-specified in the current version of the protocol, be provided by CytoSorbents and its newly appointed CRO, to improve the monitoring of patient safety endpoints. There were no specific adverse events of clinical outcomes cited in the DMC's initial recommendations following this review. To enable the efficient and thorough collection of this information for patients that have completed the trial, the DMC has recommended a pause in enrollment. CytoSorbents and its CRO plan to fulfill the requests of the DMC, which may require the filing of a protocol amendment with the FDA, in a timely manner. During this period, CytoSorbents intends to focus its clinical and financial resources to accelerate its clinical trial strategy to obtain U.S. FDA regulatory approval of CytoSorb for other specific applications, including the removal of antithrombotic agents such as ticagrelor, to reduce the severe or massive bleeding risk and significant costs in patients who undergo emergency cardiac surgery.

07:01 EST Sorrento Therapeutics trading halted, news dissemination

06:57 EST Bluegreen Vacations CEO Shawn Pearson resigns, Alan Levan to succeed - Bluegreen Vacations (BXG) announced that Shawn Pearson has resigned as President and CEO, effective December 31 for family reasons. Alan Levan will succeed Pearson as President and CEO of the company following Pearson's separation. Levan has served as Chairman of Bluegreen Vacations for over 15 years. Levan also serves as Chairman, CEO and President of BBX Capital (BBX). BBX Capital, indirectly through its wholly-owned subsidiary, Woodbridge Holdings Corporation, owns approximately 90% of the company's outstanding common stock.

06:52 EST Comstock Mining announces 1-for-5 reverse stock split - The company and the New York Stock Exchange approved and will effect a reverse split of its common stock, $0.000666 par value, at a ratio of 1-for-5, effective November 27, 2019. The Common Stock will begin trading on a split-adjusted basis when the market opens on November 29, 2019. The Reverse Split will result in each outstanding five pre-split shares of Common Stock automatically combining into one new share of Common Stock without any action on the part of the stockholders. The total number of outstanding common shares will be reduced from approximately 126M to approximately 26M shares. The company's authorized number of shares of Common Stock of the company will also be proportionately decreased from 790,000,000 to 158,000,000 shares. The company also voluntarily applied the reverse split to its 2011 Equity Plan, reducing available shares from 2,269,200 authorized performance-based management incentive shares to 453,840 available shares. No fractional shares will be issued as a result of the Reverse Split as any fractional shares resulting from the Reverse Split will be rounded up to the nearest whole share.

06:47 EST General Electric names Carolina Dybeck Happe as CFO, effective in early 2020

06:44 EST Toronto-Dominion to assume ownership stake in Charles Schwab - TD Bank Group (TD) announced its support for the acquisition of TD Ameritrade (AMTD), of which the Bank is a major shareholder, by Charles Schwab (SCHW), through a definitive agreement announced by those companies earlier this morning. Under the terms of the transaction, all TD Ameritrade shareholders, including TD, would exchange each TD Ameritrade share they own for 1.0837 shares of Schwab, which represents a 17% premium over the volume weighted-average price exchange ratio over the 30 trading days ending November 20, 2019. As a result, TD will exchange its approximate 43% ownership in TD Ameritrade for a 13.4% stake in Schwab, consisting of up to 9.9% voting common shares and the remainder in non-voting common shares, convertible upon transfer to a third party. TD and Schwab have entered into a new Stockholders' Agreement that will become effective upon closing, under which TD will have two seats on Schwab's Board of Directors. Under the agreement, TD will be subject to customary standstill and lockup restrictions. TD and Schwab have also entered into a revised IDA agreement that will become effective upon closing, and that will continue to provide TD with a profitable earnings stream. Starting on July 1, 2021, IDA deposits, which were $103B as at July 31, 2019, can be reduced at Schwab's option by up to $10B a year, with a floor of $50B. The term of the revised IDA agreement extends to 2031. The servicing fee under the revised IDA agreement will be set at 15 bps upon closing. This transaction adds significant value to TD's investment and TD expects to record a sizeable revaluation gain at closing. As Schwab realizes anticipated significant synergies and growth from the transaction, TD expects its share of Schwab's earnings to increase proportionately, more than offsetting the impact of the lower revenues under the revised long-term IDA agreement. Overall the effect on TD's earnings per share is expected to be modestly accretive once integration is complete. Upon closing, we also expect the transaction to have minimal capital impact to TD. The transaction is subject to certain closing conditions, including majority approval by the shareholders of each of TD Ameritrade and Schwab, and majority approval of TD Ameritrade's shareholders other than TD and certain other shareholders of TD Ameritrade that have entered into voting agreements. In addition, the transaction is subject to receipt of regulatory approvals. TD has agreed to vote its TD Ameritrade shares in favour of the transaction. The transaction is expected to close in the second half of calendar 2020, subject to all applicable closing conditions having been satisfied.

06:31 EST Astronics Announces collaboration with CMC - Astronics announced a new cooperation with China National Machinery Import and Export Corporation. The collaboration between Astronics and CMC will create a channel for Astronics to provide Chinese airlines, OEMs and service providers with state-of-the-art inflight entertainment and connectivity hardware and certification services for compliance in China and the United States.

06:23 EST Alexandria Real Estate launches innovation consortium in Greater Boston - Alexandria Real Estate (ARE) announced the launch of a consortium to catalyze advanced biological innovation and manufacturing in Greater Boston. As a founding member of this consortium of academic institutions, research hospitals and life science industry partners in Massachusetts, Alexandria will serve on the board of directors alongside Harvard University, the Massachusetts Institute of Technology, Fujifilm Diosynth Biotechnologies and GE (GE) Healthcare Life Sciences. Additional contributing members include Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, MilliporeSigma and the Commonwealth of Massachusetts. The consortium has convened to address the critical need for the development of important advanced technologies and to meet the region's strong demand for increased access to next-generation cell and viral vector manufacturing production, as well as to provide a novel workforce development platform to help accelerate the translation of emerging technologies into transformative medicines that aim to treat, prevent or even cure diseases. Alexandria's operating asset base in Greater Boston consists of more than 6.5M RSF of highly leased office/laboratory space, including 5M RSF in the Cambridge submarket. With an additional 1M RSF of value-creation development projects targeted for delivery through 2022, Alexandria brings to the consortium an ability to plan the site selection and technical implementation of the new center for advanced technologies innovation and manufacturing, in close proximity to the institutions, hospitals and companies seeking enhanced access to manufacturing capabilities that will speed up development for a new era of life-changing medicines.

06:11 EST TD Ameritrade names Stephen Boyle interim President and CEO - TD Ameritrade (AMTD) Board of Directors has suspended its previously disclosed CEO search, naming Stephen Boyle, TD Ameritrade EVP and CFO, as the company's interim President and CEO. Boyle will assume leadership of the company effective immediately, guiding its management team through its fiscal 2020 plan and the proposed integration with Schwab (SCHW). "Partnering with Schwab on this transformative opportunity makes the right strategic and financial sense for TD Ameritrade," Boyle said. "We share a common history-a journey since 1975 that has made Wall Street more accessible and financial dreams more attainable for millions of Americans. Our associates are fiercely proud of that legacy and all that we have accomplished to make TD Ameritrade one of the premier firms in financial services. Now we look to join forces with a respected firm like Schwab that shares our relentless focus, and to do more than we could do apart. Together, we can deliver the ultimate client experience for retail investors and independent registered investment advisors. We can continue to challenge the status quo, pooling our resources and expertise to transform lives-and investing-and deliver sustainable, long-term value to our many stakeholders."

06:08 EST Fortis names David Hutchens as COO, effective January 1, 2020 - Barry Perry, President and CEO of Fortis announced the appointment of David Hutchens as COO, Fortis, effective January 1, 2020. Hutchens was appointed Executive Vice President, Western Utility Operations with Fortis in January 2018. In this role, Hutchens continued as President & CEO of UNS Energy and provided oversight to FortisBC and FortisAlberta operations. He has been with UNS Energy for 24 years, advancing through various management positions overseeing wholesale energy trading and marketing, and energy efficiency and resource planning.

06:05 EST Kirkland Lake Gold to acquire Detour Gold Corporation in about C$4.9B deal - Kirkland Lake Gold Ltd. and Detour Gold Corporation announced announce that they have entered into a definitive agreement whereby Kirkland Lake Gold will acquire all of the issued and outstanding securities of Detour Gold pursuant to a plan of arrangement. Under the terms of the Transaction, all of the issued and outstanding common shares of Detour Gold will be exchanged at a ratio of 0.4343 of a Kirkland Lake Gold common share for each Detour Gold common share. Upon completion of the Transaction, existing Kirkland Lake Gold and Detour Gold shareholders will own approximately 73% and 27% of the pro forma company, respectively. The exchange ratio implies consideration of C$27.50 per Detour Gold common share based on the closing price of the Kirkland Lake Gold common shares on the Toronto Stock Exchange on November 22, 2019, representing a 24% premium to the closing price of the Detour Gold shares on the TSX on November 22, 2019. Based on the 20-day volume weighted average price of the Kirkland Lake Gold shares and the Detour Gold shares on the TSX for the period ending November 22, 2019, the exchange ratio implies a premium of 29% to Detour Gold shareholders. The implied equity value of the Transaction is equal to approximately C$4.9B. In addition to shareholder and court approvals, the Transaction is subject to applicable regulatory approvals including, but not limited to, TSX approval and approval under the Competition Act and the satisfaction of certain other closing conditions customary in transactions of this nature.

06:03 EST Charles Schwab to acquire TD Ameritrade in $26B all-stock transaction - Charles Schwab (SCHW) and TD Ameritrade (AMTD) announced that they have entered into a definitive agreement for Schwab to acquire TD Ameritrade in an all-stock transaction valued at approximately $26B. Under the agreement, TD Ameritrade stockholders will receive 1.0837 Schwab shares for each TD Ameritrade share, which represents a 17% premium over the 30-day volume weighted average price exchange ratio as of November 20, 2019. With today's announcement, the TD Ameritrade Board of Directors has suspended its previously disclosed CEO search, naming Stephen Boyle, TD Ameritrade EVP and CFO, as the company's interim President and CEO. Boyle will assume leadership of the company effective immediately, guiding its management team through its fiscal 2020 plan and the proposed integration with Schwab. In addition, this transaction included a renegotiation of the Insured Deposit Account (IDA) agreement by Schwab and TD Bank, to be effective at closing. The agreement was extended for a 10-year term beginning in 2021, and the servicing fee paid by Schwab on balances within the IDA was reduced by 10 basis points. Over time, Schwab will have the option to reduce balances routed to the IDA sweep program, subject to certain restrictions. This arrangement provides flexibility to optimize related revenue as those balances are shifted to Schwab. With anticipated synergies, the deal is expected to be 10-15% accretive to GAAP EPS and 15-20% accretive to Operating Cash EPS in year three, post-close. Focusing on expenses, current estimates are for approximately $1.8 to $2 billion run-rate expense synergies, which represents approximately 18-20% of the combined cost base. Some of the expense synergies the combined firm expects to realize will come from elimination of overlapping and duplicative roles. Additional synergies are expected to be achieved through real estate, administrative and other savings. Details on these synergies will be shared at a later date, once the integration process is underway. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals and approval by the stockholders of both companies. Closing is also subject to a "majority of the minority" TD Ameritrade stockholder approval condition, which means that the transaction must be approved by holders of a majority of the outstanding TD Ameritrade shares, other than TD Bank and certain other shareholders of TD Ameritrade that have entered into voting agreements. TD Bank and certain stockholders of TD Ameritrade (who collectively own approximately 52% of the TD Ameritrade shares), and certain stockholders associated with Charles R. Schwab (who own approximately 10% of the Schwab shares), have agreed to vote their shares in favor of the transaction. The parties expect the transaction to close in the second half of 2020, and integration efforts to begin immediately thereafter. Following the close of the transaction, TD Bank will have the right to name two new seats on the Schwab Board of Directors and TD Ameritrade will name a single director.

06:00 EST Charles Schwab to acquire TD Ameritrade in $26B all-stock transaction

05:40 EST Chubb agrees to purchase additional 15.3% of Huatai, stake increased to 46.2% - Chubb announced that it has agreed to purchase an additional 15.3% of Huatai Insurance Group Company Limited. Upon completion of the share purchases, Chubb is expected to own 46.2% of Huatai Insurance Group. Last week, the China Banking and Insurance Regulatory Commission, or CBIRC, approved other unrelated share purchases previously agreed to that upon closing bring Chubb's stake to 30.9%. Chubb will purchase the shares from the Inner Mongolia Junzheng Energy and Chemical Group Co., Ltd. and one of its wholly owned subsidiaries. The parties have also agreed to the intended terms of a subsequent purchase of an additional 7.1% of the company, contingent upon the completion of the first purchase. The transactions are subject to regulatory approvals and other important conditions.

05:34 EST Chi-Med: FDA grants Orphan Drug designation to surufatinib for treatment of NET - Hutchison China MediTech, or Chi-Med, announces that the FDA has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors, or NET. "NET is an area of significant unmet medical need. The current treatment options are very limited," said Christian Hogg, CEO of Chi-Med. "The FDA granting Orphan designation is a positive step and continues to reinforce the importance of our research and development in bringing surufatinib to more patients in need." If approved by the FDA as an orphan treatment, surufatinib will be entitled to seven years of market exclusivity for the approved indication. Orphan Drug designation also affords certain development cost benefits in the U.S. Surufatinib is under investigation in multiple solid tumors in China and the U.S., both as a monotherapy and in combination with immunotherapies.

05:31 EST Uber calls London decision not to renew license 'extraordinary and wrong' - Uber Technologies (UBER) said via Twitter, "@TfL's decision not to renew Uber's license in London is extraordinary and wrong, and we will appeal...We have fundamentally changed our business over the last two years and are setting the standard on safety. TfL found us to be a fit and proper operator just two months ago, and we continue to go above and beyond...On behalf of the 3.5 million riders and 45,000 licensed drivers who depend on Uber in London, we will continue to operate as normal and will do everything we can to work with @TfL to resolve this situation." Shares of Uber are down 6% to $27.70 in premarket trading while competitor Lyft (LYFT) is up 32c to $46.78.

05:28 EST Uber shares fall 6% to $27.70 after London denies new operator license

05:27 EST Uber denied new operator's license by London's transport regulator - Transport for London has concluded that it will not grant Uber London Limited (UBER) a new private hire operator's licence in response to its latest application. The agency said in a statement, "As the regulator of taxi and private hire services in London, TfL is required to make a decision on Uber's fitness and propriety before its current licence expires. Safety is TfL's number one priority. Uber has made a number of positive changes and improvements to its culture, leadership and systems in the period since the Chief Magistrate granted it a licence in June 2018. This includes interacting with TfL in a transparent and productive manner. However, TfL has identified a pattern of failures by the company including several breaches that placed passengers and their safety at risk. Despite addressing some of these issues, TfL does not have confidence that similar issues will not reoccur in the future, which has led it to conclude that the company is not fit and proper at this time. In September Uber was granted a two-month licence as further information was required on these issues, some of which emerged late in the process of its reapplication. A key issue identified was that a change to Uber's systems allowed unauthorised drivers to upload their photos to other Uber driver accounts. This allowed them to pick up passengers as though they were the booked driver, which occurred in at least 14,000 trips - putting passenger safety and security at risk. This means all the journeys were uninsured and some passenger journeys took place with unlicensed drivers, one of which had previously had their licence revoked by TfL."

05:22 EST Genentech: FDA grants priority review to risdiplam for SMA - Genentech, a member of the Roche Group, announced that the FDA has accepted the New Drug Application, or NDA, and granted Priority Review for risdiplam, an investigational survival motor neuron-2, or SMN-2, splicing modifier for spinal muscular atrophy, or SMA. Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body. The FDA is expected to make a decision on approval by May 24, 2020. "The FIREFISH and SUNFISH trials were designed to represent the real world spectrum of people living with SMA and include many people previously underrepresented in clinical trials," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We look forward to working closely with the FDA to explore broad access to risdiplam for all individuals in the community who might benefit." The risdiplam NDA submission incorporates 12-month data from the dose-finding Part 1 sections of the FIREFISH and SUNFISH pivotal studies, as well as data from the confirmatory Part 2 of SUNFISH. FIREFISH is an open-label, two-part seamless pivotal clinical trial in infants with Type 1 SMA. Part 1 was a dose-escalation study in 21 infants aged 1-7 months. The primary objective of Part 1, which evaluated efficacy as an exploratory endpoint, was to assess the safety profile of risdiplam in infants and determine the dose for Part 2, which is a pivotal, single-arm trial evaluating risdiplam in 41 infants with Type 1 SMA for 24 months, followed by an open-label extension.